We're in beta — help us improve the future of brain health!

Benefits of Testing

Early testing is the key to better care and more time

Early detection of elevated p-tau217 offers meaningful benefits for managing cognitive changes related to Alzheimer’s disease. Identifying these early signals gives you and your loved ones the time and clarity to make informed decisions, plan for the future, and access the right medical guidance and support. By understanding your brain health sooner, you gain a proactive advantage in protecting memory and overall cognitive wellness.

The Difference Early Testing Can Make

Understanding the benefits of testing for Alzheimer’s disease provides crucial insights that empower informed decisions, proactive planning, and strategies to maintain quality of life for you and your loved ones.

Take Action Years Earlier

Our biomarker blood test and our cognitive assessment provide predictive insights into your brain health. Together, the results give you a baseline assessment of your brain health and guidance of follow-up care.

Slow Disease Progression

When you catch Alzheimer's early, there are many validated medical options and lifestyle changes that can help slow the progression of the disease, which may reduce your risk of cognitive decline and dementia by up to 60%.

Stay Independent Longer

With more time on your side, you are able to create strategies, support networks and a personalized care plan that can help you better maintain your independence and quality of life.

Am I a Good Candidate for Testing?

As we age, the risk of Alzheimer’s disease increases. Understanding the benefits of testing for Alzheimer’s disease can help adults 50 and older, and those with additional risk factors, take proactive steps to understand their brain health and plan for the future.

People Experiencing Memory Issues or Cognitive Changes

This includes challenges such as occasional confusion, difficulty with problem-solving, trouble keeping track of time or place, or frequent memory lapses. Early testing can provide clarity and guidance.

Adults Aged 50 and Older

Age is the most significant risk factor for Alzheimer’s, especially when combined with conditions like heart disease, diabetes, or high blood pressure. Testing offers an early window into cognitive health before noticeable symptoms appear.

Individuals with a Family History

Genetics can increase the likelihood of developing Alzheimer’s or other dementias. For adults over 40 with a family history of Alzheimer’s, testing can provide valuable early insights and support proactive planning with healthcare providers.

Empowering Action

Neurogen provides a complete ecosystem to support early detection of Alzheimer’s disease and guide proactive cognitive health planning. By acting now, you create the opportunity for better outcomes, more options, and a stronger future.

Early Testing

The Neurogen At-Home Test Kit combines advanced p-tau217 testing, a blood biomarker linked to Alzheimer’s disease, with a brief online cognitive assessment. Together, they deliver a comprehensive view of your brain health from the comfort of home, providing insight years before severe symptoms appear.

After receiving your kit, a nurse or health professional will guide you through the sample collection process to ensure accuracy and comfort.

Dedicated Neurologist

If your results indicate potential cognitive changes, a board-certified neurologist will review your findings during a telehealth consultation. You’ll receive expert guidance and next-step recommendations tailored to your unique situation.

Personalized Brain Action Plan

Based on your test results and health profile, you receive a customized Brain Action Plan. This plan provides actionable strategies to support cognitive health, empowering you to make informed lifestyle choices and care decisions for yourself or your loved ones.

“Understanding the cause of cognitive impairment at the earliest possible time is critical for identifying the most appropriate treatment pathways. The combination of Neurogen’s blood-based biomarker and ecosystem for explanation of results and care can make a big difference in patient’s treatment plans.”

- Dr. Michelle Mielke

Professor of Gerontology and Geriatric Medicine, Wake Forest University School of Medicine